{
    "body": "To what extent does HPV vaccination reduce the risk for cervical cancer?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18482556", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19901442", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19901441", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18055075", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21245659", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17318575", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20593935", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23016781", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19200838", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21289891"
    ], 
    "ideal_answer": [
        "The most effective strategy therein was vaccination of 12-year-olds, plus a temporary 12-24-year-old catch-up program covering both sexes; whereby HPV 6/11/16/18-related cervical cancer, high-grade cervical precancer, and genital wart incidence was reduced by 84-98% during year 50 following vaccine introduction. Vaccine efficacy in prevention of CIN 2 or higher lesions in HPV 16 or HPV 18 negative women, who received all vaccination doses, ranges between 98% and 100%"
    ], 
    "exact_answer": [
        "Cervical precancer and similar neoplasias were reduced by 84-100%"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014611", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053918", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014612", 
        "http://www.disease-ontology.org/api/metadata/DOID:4362"
    ], 
    "type": "factoid", 
    "id": "531a3a58b166e2b806000037", 
    "snippets": [
        {
            "offsetInBeginSection": 891, 
            "offsetInEndSection": 1126, 
            "text": "The success of HPV vaccination as a major public health prevention opportunity, however, will entirely depend on efficient infrastructures to deliver the vaccines and on the acceptance by individuals, parents and health care providers.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17318575", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 499, 
            "offsetInEndSection": 811, 
            "text": "The most effective strategy therein was vaccination of 12-year-olds, plus a temporary 12-24-year-old catch-up program covering both sexes; whereby HPV 6/11/16/18-related cervical cancer, high-grade cervical precancer, and genital wart incidence was reduced by 84-98% during year 50 following vaccine introduction", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18055075", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 5, 
            "offsetInEndSection": 129, 
            "text": "the introduction of cervical screening programs, the incidence and mortality of cervical cancer has been drastically reduced", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18482556", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 855, 
            "offsetInEndSection": 1088, 
            "text": "On the assumption that the vaccine provided lifelong immunity, the cost-effectiveness ratio of vaccination of 12-year-old girls was $43,600 per quality-adjusted life-year (QALY) gained, as compared with the current screening practice", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18716299", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1573, 
            "offsetInEndSection": 1730, 
            "text": "Vaccine efficacy in prevention of CIN 2 or higher lesions in HPV 16 or HPV 18 negative women, who received all vaccination doses, ranges between 98% and 100%", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21289891", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1055, 
            "offsetInEndSection": 1209, 
            "text": "Life expectancy gained from vaccination is 13.04 years and average Quality Adjusted Life Years saved (QALYs) is 24.4 in vaccinated vs 6.29 in unvaccinated", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20593935", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 700, 
            "offsetInEndSection": 862, 
            "text": "Organized vaccination programs against HPV have the potential to prevent about 70% of cervical cancers and the vast majority of the other HPV-related conditions. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21245659", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 158, 
            "offsetInEndSection": 378, 
            "text": "However, existing data strongly suggests that as many as 440,000 cervical cancer cases and 220,000 deaths due to this malignancy will be prevented with the establishment of an effective worldwide HPV immunization program", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23016781", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 271, 
            "offsetInEndSection": 415, 
            "text": "Prophylactic HPV vaccination against HPV 16 and 18 has been shown to be highly effective in preventing HPV related malignancy in clinical trials", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19200838", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1138, 
            "offsetInEndSection": 1418, 
            "text": "Nevertheless women up to 45 years of age have been shown to exhibit strong immune responses to the bivalent HPV vaccine which might be expected to reduce the risk of HPV re-infection and address the second peak of HPV related malignancy in later life, evident over 45 years of age", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19200838", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 971, 
            "offsetInEndSection": 1148, 
            "text": "Reduced costs, simple vaccine regimes and strengthening vaccine delivery platforms for adolescents should eventually facilitate HPV vaccine introduction in developing countries.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19901441", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1013, 
            "offsetInEndSection": 1239, 
            "text": "Besides cost, there are several socio-cultural and ethical issues involved with the implementation of already developed vaccines including the acceptability of HPV vaccination by preadolescent girls and their parents in India.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19901442", 
            "endSection": "abstract"
        }
    ]
}